Ad hoc announcement pursuant to Art. 53 LR Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements Geneva, Switzerland and Radnor, Pennsylvania

Ad hoc announcement pursuant to Art.

Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Geneva, Switzerland and Radnor, Pennsylvania, November

14, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) ("Relief"), and NRx Pharmaceuticals,

Inc. (NASDAQ: NRXP) ("NRx Pharmaceuticals"), today announced that they have entered into definitive settlement agreements

to resolve their pending litigation. As part of the settlement, at a closing to be held within the next 30 days, (i) NRx Pharmaceuticals

will transfer to Relief all of the assets that it previously used in its aviptadil development program, including its regulatory filings,

patent applications, clinical data, and the formulation of the aviptadil product it was previously developing, (ii) Relief will have the

exclusive right and control going forward and the obligation to use commercially reasonable efforts to develop and commercialize an aviptadil

product, (iii) Relief has agreed to use commercially reasonable efforts to continue the existing Right to Try Program for aviptadil in

the United States for at least 2 years, (iv) Relief will pay NRx Pharmaceuticals milestone payments if it can successfully obtain commercial

approval of an aviptadil product (whether for COVID-19 or any other indication), (v) Relief will pay NRx Pharmaceuticals royalties based

on a percentage of future sales of an aviptadil product (whether for COVID-19 or any other indication), up to a maximum of $30 million

in the aggregate, (vi) NRx Pharmaceuticals has agreed not to compete in the development of an aviptadil product in the future, and (vii)

at the closing, Relief and NRx Pharmaceuticals will dismiss their pending litigation. There can be no assurances that Relief will be successful

at commercializing the aviptadil product.

About Relief Therapeutics

Relief is a Swiss, commercial-stage, biopharmaceutical

company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of

rare and ultra-rare diseases including metabolic disorders, pulmonary diseases, and connective tissue disorders. Relief's diversified

pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE ,

engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the

dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for

the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism,

including Urea Cycle Disorders ("UCDs") and Maple Syrup Urine Disease ("MSUD"). Relief also continues to develop

aviptadil for several rare pulmonary

indications. Further, Relief is in clinical development for APR-TD011, a differentiated acid oxidizing

solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening

connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. Finally, Relief is commercializing several

legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX

Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD. For more information, visit www.relieftherapeutics.com.

Follow Relief on LinkedIn.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical

company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic

stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets

the brain's NMDA receptor and is being investigated in a Phase 3 trial under a Food and Drug Administration ("FDA") Special

Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and acute suicidal ideation, an indication

for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in

patients with Sub-Acute Suicidality, potentially a substantially broader indication. The Breakthrough Therapy Designation and Special

Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement

over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single

Forward-Looking Statements

This press release contains forward-looking statements.

Forward-looking statements involve known and unknown risks and uncertainties, which may cause actual results in future periods to differ

materially from forecasted results. A number of factors, including (i) whether the parties can successfully close their settlement, and

(ii) those factors described in Relief's and NRx Pharmaceuticals' reports to the Securities and Exchange Commission under the Securities

Exchange Act of 1934 could adversely affect Relief and NRx, respectively. Copies of Relief's and NRx's filings with the SEC are

available on the SEC EDGAR database at www.sec.gov. Relief and NRx do not undertake any obligation

to update the information contained herein, which speaks only as of this date.

FOR MEDIA/INVESTOR INQUIRIES: